Rani Therapeutics (RANI) Projected to Post Earnings on Wednesday

Rani Therapeutics (NASDAQ:RANI) is expected to release its earnings data before the market opens on Wednesday, March 19th. Analysts expect Rani Therapeutics to post earnings of ($0.24) per share for the quarter.

Rani Therapeutics Stock Up 2.0 %

RANI opened at $1.54 on Tuesday. The company has a debt-to-equity ratio of 2.34, a quick ratio of 1.60 and a current ratio of 1.60. The company has a market cap of $88.23 million, a price-to-earnings ratio of -1.45 and a beta of 0.14. Rani Therapeutics has a one year low of $1.24 and a one year high of $8.75. The business’s fifty day moving average is $1.49 and its two-hundred day moving average is $1.92.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on RANI shares. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Rani Therapeutics in a research report on Friday, February 7th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $9.00 price target on shares of Rani Therapeutics in a report on Wednesday, February 26th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $12.33.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.